Agreement of diagnosis and its date for hematologic malignancies and solid tumors between medicare claims and cancer registry data.
about
The prevalence and cost of unapproved uses of top-selling orphan drugsIdentifying specific chemotherapeutic agents in Medicare data: a validation studyLinking Medicare, Medicaid, and cancer registry data to study the burden of cancers in West Virginia.Validity of claims-based stroke algorithms in contemporary Medicare data: reasons for geographic and racial differences in stroke (REGARDS) study linked with medicare claims.Linking the Ohio Cancer Incidence Surveillance System with Medicare, Medicaid, and Clinical Data from Home Health Care and Long Term Care Assessment Instruments: Paving the Way for New Research Endeavors in Geriatric OncologyUsing linked electronic data to validate algorithms for health outcomes in administrative databases.Use of Population-based Data to Demonstrate How Waitlist-based Metrics Overestimate Geographic Disparities in Access to Liver Transplant CareClinical and economic burden of peripheral T-cell lymphoma in commercially insured patients in the United States: findings using real-world claims data.Validation of Medicaid Claims-based Diagnosis of Myocardial Infarction Using an HIV Clinical CohortPerformance of claims-based algorithms for identifying incident thyroid cancer in commercial health plan enrollees receiving antidiabetic drug therapies.Incidence of health insurance claims for thyroid neoplasm and pancreatic malignancy in association with exenatide: signal refinement using active safety surveillanceTradeoffs between accuracy measures for electronic health care data algorithmsA systematic review of validated methods for identifying lymphoma using administrative data.Malignancy validation in a United States registry of rheumatoid arthritis patients.Electronic medical record cancer incidence over six years comparing new users of glargine with new users of NPH insulinDipeptidyl-peptidase-4 inhibitors and pancreatic cancer: a cohort study.Unsupported off-label chemotherapy in metastatic colon cancer.Validation of a coding algorithm to identify bladder cancer and distinguish stage in an electronic medical records database.Further exploration of the relationship between insulin glargine and incident cancer: a retrospective cohort study of older Medicare patientsTradeoffs of using administrative claims and medical records to identify the use of personalized medicine for patients with breast cancer.Trends in Anemia Management in Hemodialysis Patients with CancerDiabetes Pharmacotherapies and Bladder Cancer: A Medicare Epidemiologic StudyDisruptions in Liver Function among Cancer Patients and Patients Treated with Tyrosine Kinase Inhibiting Drugs: Comparisons of Two Population-Based DatabasesColorectal cancer incidence and screening in US Medicaid patients with and without HIV infection.Cancer incidence among US Medicare ESRD patients receiving hemodialysis, 1996-2009.Comparison of diagnostic evaluations for cough among initiators of angiotensin converting enzyme inhibitors and angiotensin receptor blockers.Comparison of prospective and retrospective indicators of the quality of end-of-life cancer care.Tumor necrosis factor α inhibitor therapy and cancer risk in chronic immune-mediated diseasesCancer incidence among those initiating insulin therapy with glargine versus human NPH insulin.Declining accuracy in disease classification on health insurance claims: should we reconsider classification by principal diagnosis?Evaluation of algorithms to identify incident cancer cases by using French health administrative databases.Comparative Effect of Initiating Metformin Versus Sulfonylureas on Breast Cancer Risk in Older Women.Identifying barriers to hepatocellular carcinoma surveillance in a national sample of patients with cirrhosis.Patients With Hepatocellular Carcinoma Have Highest Rates of Wait-listing for Liver Transplantation Among Patients With End-Stage Liver Disease.Association Between Breast Cancer Recurrence and Immunosuppression in Rheumatoid Arthritis and Inflammatory Bowel Disease: A Cohort Study.Comparative safety of pioglitazone versus clinically meaningful treatment alternatives concerning the risk of bladder cancer in older US adults with type 2 diabetes.Risk of Nonmelanoma Skin Cancer Associated With the Use of Immunosuppressant and Biologic Agents in Patients With a History of Autoimmune Disease and Nonmelanoma Skin Cancer.Effect of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors on colorectal cancer incidence and its precursors.Assembling and validating data from multiple sources to study care for Veterans with bladder cancer.Hematologic malignancies: an opportunity to fill a gap in cancer surveillance.
P2860
Q21134770-15E9361C-F169-4A6C-8707-F2E58CC4D65FQ30413422-4117CA91-5B71-46EB-8316-46BB030ACD84Q30814844-5F80A308-5833-462D-A191-6F00F0C01E65Q30833294-42D1FD09-AEA4-4D06-A818-020A2650B530Q30843385-CC7EAD75-78AD-4A3C-BCEF-D1077149CF8FQ30987366-02421E12-8A1F-49F4-A3D7-B92041680B85Q31072650-3B7D26B7-B103-44F3-B9EE-8405F2F4324DQ31092020-15215A27-FA72-4AA7-8F7B-7D84E60F7E8BQ33618727-8DA70720-A6C6-4D87-98F3-F24AFD63657AQ33644714-388A6BCC-CC57-441B-A3E1-3E2D0A8C83D8Q33949418-CEB2EA5A-9840-47EF-82F1-DE4D3B5E8EF5Q34111706-9A072A05-4394-48FB-B826-9C8A6C24C619Q34133911-69A60179-49AC-4CB3-80F4-99D098D082B8Q34287960-1709149F-BD88-44F6-BCD3-545EE36A883DQ34373861-1E5D6B14-260D-40D4-9F8E-4A4A5485D926Q34490448-65E28864-7A82-446C-8B4F-AC94AD4F33D3Q34526503-F38FB485-E113-4320-A398-D68445589441Q34964151-BF215F09-395A-48E5-B6D9-1D3F1DF1EEEBQ35179836-39A27C35-6F0E-4B5A-B90A-B5E258D16EDCQ36060162-98933E2C-5319-4FBC-983E-38397626E35FQ36200205-C3B26177-B9A6-4772-8AE0-6C4795357CAAQ36712191-492F80B7-9E5A-453A-A9AD-34E42D180258Q36845060-E1561973-E46C-41D5-B99E-12915C28576BQ36960567-0B48AA01-F3FC-455F-8AC5-F5A6110D80C9Q37045476-F46BFA5D-5E42-44FB-8D90-E8DCFB149608Q37066166-F4C225CE-2226-44D9-B425-86634FB80027Q37115363-FDDE2A04-684F-49EA-8959-7E5EE5302377Q37186231-872513E3-FFDD-462A-AEE4-C6C02D35C9C6Q37278227-6AEF26E0-D2DE-4307-A785-DE7661701AC2Q37511189-2644F1A8-E0E3-4506-97B9-690EEE8B7CCFQ38686154-B6C4F137-AD04-455E-8525-BE308FC42E04Q38976502-5726A36C-0D0F-4350-9C41-64B0997DA396Q39484209-5F12A949-8649-4A29-9725-7EADC6AD5020Q39635570-300BF507-1452-4895-A656-F355470CF907Q39783472-57F233D8-7D3C-484C-9EDA-4C434CFB2B49Q40141299-E556DC27-9B08-4991-B7A2-068C17415EB5Q40383687-5C85EFC4-6EC9-4570-88B9-6854FED12C79Q40760702-E05DF3AF-7E60-4F68-8D97-A436B8D27C81Q41624975-8BF8EEF8-E6F5-4B9B-A1EE-034D3278569DQ43676080-AC281130-44CA-44B0-8473-4C49204D74AF
P2860
Agreement of diagnosis and its date for hematologic malignancies and solid tumors between medicare claims and cancer registry data.
description
2007 nî lūn-bûn
@nan
2007 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Agreement of diagnosis and its ...... aims and cancer registry data.
@ast
Agreement of diagnosis and its ...... aims and cancer registry data.
@en
type
label
Agreement of diagnosis and its ...... aims and cancer registry data.
@ast
Agreement of diagnosis and its ...... aims and cancer registry data.
@en
prefLabel
Agreement of diagnosis and its ...... aims and cancer registry data.
@ast
Agreement of diagnosis and its ...... aims and cancer registry data.
@en
P2093
P1476
Agreement of diagnosis and its ...... aims and cancer registry data.
@en
P2093
Daniel H Solomon
E Francis Cook
Raisa Levin
Robert J Glynn
Sebastian Schneeweiss
Soko Setoguchi
P2888
P304
P356
10.1007/S10552-007-0131-1
P577
2007-04-19T00:00:00Z
P5875
P6179
1015650827